A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Glucose-6-Phosphate Dehydrogenase,Qual
MessageHematology
Test Code
LAB10035
Alias/See Also
Glucose-6-Phosphate Dehydrogenase Qualitative
G6PD
G6PD
CPT Codes
82960
Preferred Specimen
2.5 mL whole blood (lavender top tube, EDTA) For infants 200 µL (microliter) EDTA microtainer
Minimum Volume
2.5 mL
Other Acceptable Specimens
Whole blood collected with Heparin or ACD
Instructions
LAB: Store whole blood in refrigerator in hematology Dept weekends and off-hours.
Specimen Stability
Refrigerated 2 - 8° C: 1 week
Methodology
Qualitative, visual fluorescence, screening procedure for the detection of G-6-PD deficiency in whole blood. In the procedure, the reaction mixture containing glucose-6-phosphate, NADP and a small amount of blood is incubated for a few minutes. Drops from the mixture are spotted onto filter paper at zero time and at 5-minute intervals. The spots are then visually inspected under long wave UV light. Development of fluorescence will be observed with normal blood. No appreciable fluorescence appears when G-6-PD is deficient.
Setup Schedule
Test performed 0600 - 1100 Monday through Friday only.
Report Available
Test performed 0600 - 1100 Monday through Friday only. Report available upon completion.
Limitations
Leukocytes and platelets may be rich in G-6-PDH and may cause some interference in the assay if present beyond normal levels. Therefore, higher than normal levels of G-6-PD could occur in cases of leukocytosis and thrombocytosis.
Young red blood cells (reticulocytes) have higher G-6-PD levels than mature erythrocytes. A false-negative result, indicating the sample is normal, may be obtained in individuals with an anemia and resulting reticulocytosis.
Young red blood cells (reticulocytes) have higher G-6-PD levels than mature erythrocytes. A false-negative result, indicating the sample is normal, may be obtained in individuals with an anemia and resulting reticulocytosis.
Reference Range
Normal
Clinical Significance
Glucose-6-phosphate deficiency is an X-linked disorder of carbohydrate metabolism, which can result in either congenital nonspherocytic hemolytic anemia or a drug- induced hemolytic anemia. Substances capable of inducing hemolysis in affected individuals include fava beans, anti-malarial drugs, aspirin, vitamin K analogues, sulfonamides, and other compounds. This anomaly is found predominately in Mediterranean peoples, Southeast Asians, Africans, and African Americans.
Performing Laboratory
HHN